The Patent Finder

Cti Biopharma Corp.

Also on record
Records under this name other than patents Cti Biopharma Corp. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Cti Biopharma Corp.

PatentTitleStatus Expires Confidence
US 9,573,964Oxygen Linked Pyrimidine Derivatives
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 8,153,632Oxygen Linked Pyrimidine Derivatives
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,624,24211-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,987,24311-(2-Pyrrolidin-1-YL-ETHOXY)-14,19-Dioxa-5,7,26-Triaza-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-Decaene Maleate Salt
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 8,980,87311-(2-Pyrrolidin-1-YL-ETHOXY)-14,19-Dioxa-5,7,26-Triaza-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-Decaene Citrate Salt
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 9,062,074(9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,415,338Oxygen Linked Pyrimidine Derivatives
Formerly held
Term ended
Term ended Nov 15, 2026 · High confidence
Term endedTerm ended Nov 15, 2026High confidence
US 10,517,876Oxygen Linked Pyrimidine Derivatives
Formerly held
Term ended
Term ended Nov 15, 2026 · High confidence
Term endedTerm ended Nov 15, 2026High confidence
US 11,135,227Oxygen Linked Pyrimidine Derivatives
Formerly held
Term ended
Term ended Nov 15, 2026 · High confidence
Term endedTerm ended Nov 15, 2026High confidence
US 9,211,262Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
Formerly held
Term ended
Term ended Aug 9, 2024 · From the USPTO record
Term endedTerm ended Aug 9, 2024From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited